Prednisone
NDC 16590-624
View NDC Profile UNII Mappings and RxNorm Concepts.
Product Information
This product is EXCLUDED from the official NDC directory because the listing data was inactivated by the FDA.
Prednisone is a ANDA-approved product labeled by Stat Rx Usa Llc. This product is primarily utilized in pharmaceutical processing or compounding. It is supplied as a white product. This product entry covers the primary NDC 16590-624 and 2 associated package configurations. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
NDC Product Code:
16590-624
Proprietary Name:
Prednisone
Product Type: [3]
INACTIVATED PRODUCT and EXCLUDED the from NDC Directory
Code Navigator:
Labeler & Regulatory Data
Labeler Name: [5]
Labeler Code:
16590
Product Label ID:
FDA Application Number: [6]
ANDA088832
Marketing Category: [8]
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Marketing Timeline
Start Marketing Date: [9]
05-19-2006
Listing Expiration Date: [11]
12-31-2017
Exclude Flag: [12]
I
Product Characteristics
Color(s):
WHITE (C48325)
Shape:
ROUND (C48348)
Size(s):
9 MM
Imprint(s):
WESTWARD;473 Score:
2
Code Structure Chart
Product Details
What is NDC 16590-624?
The NDC code 16590-624 is assigned by the FDA to the product Prednisone. This pharmaceutical product is labeled by Stat Rx Usa Llc and is currently categorized as listed product. In terms of distribution, this product is available in 2 different package configurations. The associated package NDC(s) include: 16590-624-21, 16590-624-48. Beyond standard identification, this entry provides technical data including pharmacologic classes, UNII ingredient references, and RxNorm cross-referencing for healthcare systems.
What are the uses of this product?
Prednisone tablets are indicated in the following conditions:Endocrine disorders: primary or secondary
adrenocortical insufficiency (hydrocortisone or cortisone is the first choice;
synthetic analogs may be used in conjunction with mineralocorticoids where
applicable; in infancy mineralocorticoid supplementation is of particular
importance), congenital adrenal hyperplasia, nonsuppurative thyroiditis,
hypercalcemia associated with cancer.Rheumatic disorders: as adjunctive therapy for
short-term administration (to tide the patient over an acute episode or
exacerbation) in; psoriatic arthritis; rheumatoid arthritis, including juvenile
rheumatoid arthritis (selected cases may require low-dose maintenance therapy);
ankylosing spondylitis; acute and subacute bursitis; acute nonspecific
tenosynovitis; acute gouty arthritis; post-traumatic osteoarthritis; synovitis
of osteoarthritis; epicondylitis.Collagen diseases: during an exacerbation or as
maintenance therapy in selected cases of: systemic lupus erythematosus, systemic
dermatomyositis (polymyositis), acute rheumatic carditis.Dermatologic diseases: pemphigus, bullous
dermatitis herpetiformis, severe erythema multiforme (Stevens-Johnson syndrome),
exfoliative dermatitis, mycosis fungoides, severe psoriasis, severe seborrheic
dermatitis.Allergic states: control of severe or
incapacitating allergic conditions intractable to adequate trials of
conventional treatment: seasonal or perennial allergic rhinitis, serum sickness,
bronchial asthma, contact dermatitis, atopic dermatitis, drug hypersensitivity
reactions.Ophthalmic diseases: severe acute and chronic
allergic and inflammatory processes involving the eye and its adnexa, such as:
allergic conjunctivitis, keratitis, allergic corneal marginal ulcers, herpes
zoster ophthalmicus, iritis and iridocyclitis, chorioretinitis, anterior segment
inflammation, diffuse posterior uveitis and choroiditis, optic neuritis,
sympathetic ophthalmia.Respiratory diseases: symptomatic sarcoidosis,
Loeffler’s syndrome not manageable by other means, berylliosis, fulminating or
disseminated pulmonary tuberculosis when used concurrently with appropriate
antituberculous chemotherapy, aspiration pneumonitis.Hematologic disorders: Idiopathic thrombocytopenic
purpura in adults, secondary thrombocytopenia in adults, acquired (autoimmune)
hemolytic anemia, eythroblastopenia (RBC anemia), congenital (erythroid)
hypoplastic anemia.Neoplastic diseases: for palliative management of:
leukemias and lymphomas in adults, acute leukemia of childhood.Edematous states: to induce a diuresis or
remission of proteinuria in the nephritic syndrome, without uremia, of the
idiopathic type or that due to lupus erythematosus.Gastrointestinal diseases: to tide the patient
over a critical period of the disease in: ulcerative colitis, regional
enteritis.Miscellaneous: tuberculous meningitis with
subarachnoid block or impending block when used concurrently with appropriate
antituberculous chemotherapy, trichinosis with neurologic or myocardial
involvement.
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- PREDNISONE (UNII: VB0R961HZT)
- PREDNISONE (UNII: VB0R961HZT) (Active Moiety)
What is the NDC to RxNorm Crosswalk for this product?
RxNorm is a normalized naming system for generic and branded drugs that assigns unique concept identifier(s) known as RxCUIs to NDC products.The NDC to RxNorm Crosswalk for this produdct indicates multiple concept unique identifiers (RXCUIs) are associated with this product:
- RxCUI: 198145 - predniSONE 10 MG Oral Tablet
- RxCUI: 198145 - prednisone 10 MG Oral Tablet
- RxCUI: 763183 - {48 (prednisone 10 MG Oral Tablet) } Pack
- RxCUI: 763183 - predniSONE 10 MG Tablet 12 Day 48 Count Pack
- RxCUI: 763183 - Prednisone 10 MG Oral Tablet 48 Count Pack
* Please review the full disclaimer at the bottom of this page.
Product & Regulatory Definitions
What is the Labeler Name? Name of Company corresponding to the labeler code segment of the Product NDC.
What is the FDA Application Number? This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
What is the Marketing Category? Product types are broken down into several potential Marketing Categories, such as NDA/ANDA/BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
What is the Start Marketing Date? This is the date that the labeler indicates was the start of its marketing of the drug product.
What is the Listing Expiration Date? This is the date when the listing record will expire if not updated or certified by the product labeler.
What is the NDC Exclude Flag? This field indicates whether the product has been removed/excluded from the NDC Directory for failure to respond to FDA"s requests for correction to deficient or non-compliant submissions, or because the listing certification is expired, or because the listing data was inactivated by FDA, or because it was discontinued by the labeler. Possible values in this field are: "D", "E", "I", "N", "U".